This volume highlights recent advances using iPS cells in disease modeling and medical applications along with new technologies that enhance the power of iPS cells. While the discovery of iPS cells has provided excellent opportunities for developing models of human diseases, platforms for drug discovery and cell therapies, iPS cell technology still faces many challenges. Presenting the latest advances in this rapidly evolving research area, this book is intended to widen the community of researchers and clinicians interested in the exciting field of iPS cells.

Herbal Medicines: A Boon for Healthy Human Life provides a comprehensive overview of the role of herbal medicines for treating a broad variety of human diseases, from neurological disorders to cancer and major disorders such as infectious diseases, metabolic disorders, and more. Each chapter summarizes the current state and future direction of the use of herbal medicines against multiple diseases from a translational point-of-view, making this reference a valuable source of information for a large audience, including researchers and healthcare providers interested in the field of herbal remedies. - Discusses essential evidence-based information about herbal medicines - Provides an update to new discoveries and recent advances on the use of herbal medicines to treat multiple human diseases - Includes information on clinical studies and covers all major medicinal compounds, including alkaloids, glycosides, polyphenols and terpenes

Sirtuin Biology in Cancer and Metabolic Disease: Cellular Pathways for Clinical Discovery offers a compelling and thought-provoking perspective for the examination of the intriguing biology of sirtuins that ties cancer and metabolic disease together and provides a critical platform for the development of sirtuin-based novel therapeutic strategies to effectively treat cancer and metabolic disorders with precision in order to minimize any potentially detrimental clinical outcomes. An exciting prospect for the development of innovative therapeutics for cancer and metabolic disorders involves sirtuins. Sirtuins are histone deacetylases that have an intricate role in the onset and development of cancer and metabolic disease. Implementing a translational medicine format, this innovative reference highlights the ability of sirtuins to oversee critical pathways that involve stem cell maintenance, cellular proliferation, metabolic homeostasis, apoptosis, and autophagy that can impact cellular dysfunction and unchecked cellular growth that can occur during cancer and metabolic disease. Each chapter offers an intuitive perspective of advances on the application of sirtuin pathways for cancer and metabolic disease that will be become a "go-to" resource for a broad audience of scientists, physicians, pharmaceutical industry experts, nutritionists, and students. - Chapters are authored by internationally recognized experts who elucidate the intimate relationship between cancer and metabolic disease that intersects with sirtuin pathways - Presents the basic and clinical role of sirtuins in regard to cancer and metabolic disease - Summarizes the multidiscipline views and publications for this exciting field of sirtuins for the development of new clinical treatments for cancer and metabolic disease - Provides a vital foundation for a broad audience of healthcare providers, scientists, drug developers, and students in both clinical and research settings

Breast cancer is the most common tumor in females worldwide. Cancer epigenetics and metabolic reprogramming are known cancer hallmarks. Recent advances in the field of epigenetics include histone modification, DNA methylation, and non-coding RNAs. In contrast to genetic modifications, epigenetics refers to a set of dynamic alterations. By controlling the on and off states of oncogenes and tumor suppressor genes, as well as re-engineering the tumor microenvironment, epigenetics plays a crucial role in the initiation and progression of carcinogenesis. Additionally, the complex process of metabolic reprogramming is required for both malignant transformation and tumor development, including invasion and metastasis. Furthermore, reprogrammed metabolic activities have been utilized to diagnose, monitor, and treat cancer patients. In tumor tissues, metabolic heterogeneity was found to take a role in the adaptation to the microenvironment drastic changes resulting from current therapeutic modalities.